Payment overview · 2025
General Payments
$405.61
25 reported records · 5 companies
Healthcare provider profile · identity verified
Jerald B Taylor, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · NEPHI, UT · NPI 1083631659
Verified facts
What the public records show
CMS Open Payments records show Jerald B Taylor, D.O. received $405.61 in general payments during 2025 across 25 reported records.
ABBVIE INC. accounted for 82.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $336.20 | 82.9% | 21 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $25.75 | 6.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.57 | 3.8% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $15.11 | 3.7% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $12.98 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $405.61 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $233.53 | 15 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $102.67 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $102.67 | 6 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $25.75 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $12.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
138 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 501 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 432 | 95 |
| Omeprazole | Omeprazole | 336 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 280 | 60 |
| Lisinopril | Lisinopril | 256 | 55 |
| Gabapentin | Gabapentin | 249 | 55 |
| Losartan Potassium | Losartan Potassium | 198 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 189 | 39 |
| Simvastatin | Simvastatin | 163 | 29 |
| Furosemide | Furosemide | 159 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 158 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 37 |
| Eliquis | Apixaban | 138 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 21 |
| Alendronate Sodium | Alendronate Sodium | 107 | 24 |
| Metformin Hcl | Metformin Hcl | 107 | 21 |
| Metformin Hcl Er | Metformin Hcl | 104 | 26 |
| Glimepiride | Glimepiride | 97 | 21 |
| Bupropion Xl | Bupropion Hcl | 94 | 19 |
| Potassium Chloride | Potassium Chloride | 93 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 30 |
| Trazodone Hcl | Trazodone Hcl | 83 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 81 | 21 |
| Allopurinol | Allopurinol | 80 | 17 |
| Sertraline Hcl | Sertraline Hcl | 80 | 16 |
| Meloxicam | Meloxicam | 77 | 16 |
| Montelukast Sodium | Montelukast Sodium | 76 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 71 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | suppressed |
| Cefdinir | Cefdinir | 63 | 59 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 16 |
| Finasteride | Finasteride | 55 | suppressed |
| Topiramate | Topiramate | 53 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | suppressed |
| Prednisone | Prednisone | 50 | 40 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 47 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | suppressed |
| Tradjenta | Linagliptin | 45 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | suppressed |
| Nystatin | Nystatin | 42 | 13 |
| Carvedilol | Carvedilol | 40 | 14 |
| Tramadol Hcl | Tramadol Hcl | 40 | 11 |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Ibuprofen | Ibuprofen | 37 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Sucralfate | Sucralfate | 35 | 13 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Cephalexin | Cephalexin | 29 | 15 |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 20 |
| Celecoxib | Celecoxib | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 18 |
| Lorazepam | Lorazepam | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 20 |
| Baclofen | Baclofen | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nortrel | Norethindrone-Ethin. Estradiol | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Tacrolimus | Tacrolimus | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Alogliptin | Alogliptin Benzoate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Ec-Naproxen | Naproxen | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $405.61 · 25 records | ABBVIE INC. | BEYFORTUS, Hillrom - Vest System Model 105 Home Care, NEXPLANON, QULIPTA, UBRELVY, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error